Literature DB >> 7527818

Monoclonal IgM rheumatoid factor secreted by CD5-negative B cells during mixed cryoglobulinemia. Evidence for somatic mutations and intraclonal diversity of the expressed VH region gene.

R Crouzier1, T Martin, J L Pasquali.   

Abstract

Mixed cryoglobulinemia is usually considered to be a nonmalignant human B cell proliferation that produces a monoclonal IgM rheumatoid factor (RF). Important immunologic similarities and differences were described between the monoclonal B cells during mixed cryoglobulinemia and during malignant chronic lymphocytic leukemia (CLL):high frequency of the same VH and V kappa gene usage by both types of monoclonal B cells producing IgM with RF activity, apparent intraclonal homogeneity, but different expression of the pan T cell CD5 Ag. The description of an unusual CD5-negative B cell CLL case secreting a mutated IgM RF led the authors to suggest that the usage of non-mutated germline Ig genes is a property of cells derived from the CD5 lineage or stage of differentiation, rather than an intrinsic property of CLL or of IgM RF-producing cells in general. Because mixed cryoglobulinemia cells are usually CD5-negative, it was of interest to test for the existence of mutations in the VH and V kappa regions, as well as for the intraclonal homogeneity of the expressed Ig genes. In this study, we used the PCR technique to analyze the monoclonal rheumatoid factor (mRF) V genes from a patient with mixed cryoglobulinemia. We show that the CD5-negative monoclonal B cells express a slightly mutated V kappa 3 gene, but a more mutated VH1 gene whose genomic counterpart was shown to be the 51p1 germline gene. The sequence analysis of several independent clones shows some degree of intraclonal diversity, suggesting the existence of a clonal filiation. These results are discussed in terms of the origin of the monoclonal B cell during mixed cryoglobulinemia and CLL.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7527818

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Hepatitis C virus infection and lymphoproliferative disorders.

Authors:  L R Peña; S Nand; N De Maria; D H Van Thiel
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

2.  Cryoglobulins are not essential.

Authors:  M Trendelenburg; J A Schifferli
Journal:  Ann Rheum Dis       Date:  1998-01       Impact factor: 19.103

3.  Hepatitis C virus (HCV) in lymphocyte subsets and in B lymphocytes expressing rheumatoid factor cross-reacting idiotype in type II mixed cryoglobulinaemia.

Authors:  A Fornasieri; P Bernasconi; M L Ribero; R A Sinico; M Fasola; J Zhou; G Portera; A Tagger; A Gibelli; G D'amico
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

Review 4.  The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection.

Authors:  V Agnello
Journal:  Springer Semin Immunopathol       Date:  1997

5.  Characterization of the light chain-restricted clonal B cells in peripheral blood of HCV-positive patients.

Authors:  Korenori Ohtsubo; Michio Sata; Takumi Kawaguchi; Satoshi Morishige; Yuka Takata; Eijiro Oku; Rie Imamura; Ritsuko Seki; Michitoshi Hashiguchi; Koichi Osaki; Kazuaki Yakushiji; Taisuke Kanaji; Kohji Yoshimoto; Takato Ueno; Takashi Okamura
Journal:  Int J Hematol       Date:  2009-04-08       Impact factor: 2.490

6.  Effect of 51p1-related gene copy number (V1-69 locus) on production of hepatitis C-associated cryoglobulins.

Authors:  E H Sasso; P Ghillani; L Musset; J C Piette; P Cacoub
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

7.  Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia.

Authors:  Edgar D Charles; Rashidah M Green; Svetlana Marukian; Andrew H Talal; Gerond V Lake-Bakaar; Ira M Jacobson; Charles M Rice; Lynn B Dustin
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

8.  A case report of pre-eclampsia-like endothelial injury in the kidney of an 85-year-old man treated with ibrutinib.

Authors:  Amy Li; Sophia L Ambruso; Ozgur Akin Oto; Marc Barry; Charles L Edelstein
Journal:  BMC Nephrol       Date:  2022-07-23       Impact factor: 2.585

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.